Boston Scientific Corporation announced that its subsidiary, Boston Scientific Japan K.K., has reached an agreement with Fukuda Denshi Co., Ltd. to market and sell its Cardiac Rhythm Management (CRM) devices and accessories throughout Japan. Fukuda Denshi's extensive sales resources, distribution network and service capabilities will complement Boston Scientific's existing sales and marketing organization and allow the Company to reach substantially more accounts and expand the service it offers to its customers in Japan. Fukuda Denshi will begin distributing Boston Scientific CRM products this quarter.
“We are pleased to reach agreement with Fukuda Denshi to distribute our CRM products in Japan,” said Maulik Nanavaty, president of Boston Scientific Japan. “Our enhanced sales, distribution and service capabilities will help us better serve Japanese physicians and their patients while broadening our reach and growing our market share in this important market. Fukuda Denshi has been an established player in Japan for more than 70 years, with a proven track record and a long and successful history of delivering results. We look forward to a successful partnership with them.”
Boston Scientific is a leading developer of implantable devices used to treat cardiac arrhythmias (abnormal heart rhythms), sudden cardiac arrest and heart failure. The Company's advanced product portfolio includes pacemakers, Implantable Cardioverter Defibrillators (ICDs), Cardiac Resynchronization Therapy Defibrillators (CRT-Ds), cardiac leads and patient management systems.
Fukuda Denshi is a global leader in the research and development, manufacture and sale of medical electronics equipment Its annual revenues exceed $1 billion.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.